Since the publication in 1998 of the last special issue of JGPN on the genetics of dementia, we have witnessed the completion of the Human Genome Project and an exponential increase in the identification of causative genes in human diseases. This special issue revisits the 6 neurodegenerative disorders described in that issue, offering important updates to the genetic findings for these disorders that together comprise the most common causes of dementia among elderly people. It is critical for practicing neurologists, psychiatrists, and geriatricians to keep abreast of these advances as they will impact the clinical diagnosis and management of these disorders. The reviews in this issue have been written by an outstanding group of international experts who provide a clear and insightful update on the molecular genetic advances and genetic counseling principles for each disorder.
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Alzheimer disease (AD) is the most common cause of dementia in elderly individuals. Clinically, patients initially present with short-term memory loss, which is then followed by executive dysfunction, confusion, agitation, and behavioral disturbances. In the 1990s, 3 causative genes (APP, PSEN1, and PSEN2) have been associated with autosomal dominant familial AD. In addition, 1 genetic risk factor (APOE*4 allele) has been identified that increases the susceptibility for developing sporadic AD. The identification of these genes has led to a number of animal models that have been useful in studying the pathogenesis underlying AD. Drs Lynn Bekris, Chang-En Yu, Thomas Bird, and Debby Tsuang from the University of Washington review the most recent findings.
Parkinson disease (PD) is the second most common cause of dementia in elderly people. Patients with PD are characterized clinically by their development of an asymmetrical resting tremor (which is typically responsive to levo-dopa), postural instability, and autonomic instability. There has been tremendous research progress in the genetics of PD during the past decade, particularly with the discovery of genes underlying rare Mendelian forms of PD and of genetic risk factors that increase a person's susceptibility to developing the disease. Drs Lynn Bekris, Ignacio Fernandez, and Cyrus Zabetian from the University of Washington provide a succinct review of this blossoming field.
Huntington disease (HD) is a dominantly inherited neurodegenerative disorder that usually presents in adulthood with a classic triad of symptoms that include motor dysfunction (eg, chorea), dementia, and variable and diverse psychiatric disturbances. In 1993, scientists discovered an association between the HTT gene and HD: the HTT gene contains a variably expanded CAG trinucleotide repeat sequence encoding a polyglutamine tract, and expansion of the CAG repeat tract beyond the normal range of 10 to 35 repeats is associated with the development of HD. Since this discovery, we have made great advances in understanding the pathogenesis of HD. Drs Aaron Sturrock and Blair Leavitt from the University of British Columbia provide a summary of recent clinical trials in HD and a clear review of the existing literature.
Frontotemporal lobar degeneration (FTLD) is a neurodegenerative disorder that tends to have an onset in mid-life. Historically, the clinical syndrome of FTLD has included 3 major subtypes: behavioral variant and 2 primary progressive aphasia syndromes. In the past decade, 7 chromosomal loci on 3 different chromosomes have been linked to familial FTLD, and mutations in 2 genes located on the same chromosome (MAPT and GRN) have been shown to cause a number of cases with autosomal dominant FTLD. Drs Tricia See, Amanda LaMarre, Suzee Lee, and Bruce Miller from the University of California, San Francisco, provide a comprehensive update on the genetic causes of FTLD, including genetic, molecular, pathological, and phenotypic variations that are associated with each of the FTLD gene mutations, as well as markers that may help differentiate between the 2 causative mutations.
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a rare dominantly inherited small artery disease that leads to disability and dementia in mid-life. The clinical presentation is quite variable between families and can include migraines with aura, subcortical ischemic events, mood disturbances, apathy, and cognitive impairments. In 1996, linkage studies of several families with CADASIL identified the mutated gene NOTCH3 on chromosome 19. Drs Dominique Hervé and Hugue Chabriat from the Service de Neurologie, Hôpital Lariboisière in Paris, France, provide a review of the latest genetic findings of this disorder.
Finally, the prion diseases are a family of rare neurodegenerative disorders that result from the accumulation of a misfolded isoform of the prion protein (PrP), a normal constituent of the neuronal membrane. Five subtypes constitute the known human prion diseases: kuru, Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker syndrome (GSS), fatal insomnia (FI), and variant CJD (vCJD). Although these subtypes can be distinguished clinically, differentiation is primarily determined by differences in the pathogenic conformation of misfolded PrP on brain histopathology. Drs Khalilah Brown and James Mastrianni from the University of Chicago review some of the general background related to prion biology and then detail the clinical and pathologic features of the major prion diseases, with particular attention to the genetic aspects that result in prion disease or modification of its risk or phenotype.
Although molecular genetics has helped to clarify the etiology of these disorders, clinicians have played a critical role in the careful identification and classification of many families who were involved in the eventual mapping and cloning of causative mutations. Thus, the role of the clinician should not be underestimated, and the continued participation of clinicians is crucial to the future of successful clinical and molecular genetic research in neurodegenerative disorders, a future that has great promise. Indeed, it is likely that new diagnostic and therapeutic strategies for many neurodegenerative disorders are just on the horizon.
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